Corrigendum: miR-21 in Human Cardiomyopathies

Surina¹, Rosaria Anna Fontanella¹, Lucia Scisciola¹, Raffaele Marfella^{1

2}, Giuseppe Paolisso^{1

2}, Michelangela Barbieri¹

Affiliations

¹ Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
² Mediterrannea Cardiocentro, Napoli, Italy.

Published Erratum

Surina et al. Front Cardiovasc Med. 2022.

. 2022 Apr 25:9:913429.

doi: 10.3389/fcvm.2022.913429. eCollection 2022.

Surina¹, Rosaria Anna Fontanella¹, Lucia Scisciola¹, Raffaele Marfella^{1

2}, Giuseppe Paolisso^{1

2}, Michelangela Barbieri¹

¹ Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
² Mediterrannea Cardiocentro, Napoli, Italy.

Abstract

[This corrects the article DOI: 10.3389/fcvm.2021.767064.].

Keywords: biomarkers; cardiomyopathies; fibrosis; miR-21; targeted therapy.

miR-21 in Human Cardiomyopathies.
Surina S, Fontanella RA, Scisciola L, Marfella R, Paolisso G, Barbieri M. Surina S, et al. Front Cardiovasc Med. 2021 Oct 27;8:767064. doi: 10.3389/fcvm.2021.767064. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 34778418 Free PMC article. Review.